This analysis looked at patients who had acute ischemic stroke after heart rhythm procedures and were taking dabigatran. Researchers combined a case report with a systematic review to see if reversing the blood thinner with idarucizumab allowed for safe stroke treatment. The group compared these patients to others who received stroke treatment without blood thinners.
The findings suggested that reversing the medication enabled intravenous thrombolysis with low rates of intracranial hemorrhage and low mortality. Patients also showed favorable functional outcomes comparable to standard thrombolysis populations. The follow-up period for these results was 90 days.
No specific adverse events or discontinuations were reported in the available data. However, this evidence comes from a case report and meta-analysis where sample sizes were not reported. This early information suggests that reversing anticoagulants followed by prompt reperfusion therapy may be a feasible and safe strategy for carefully selected patients.